Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24219784 | 0.86 | HTT (0.51) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1643549 | 0.83 | TDP1 (0.49) | HTTNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27145365 | 0.81 | HTT (0.59) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31413386 | 0.81 | HTT (0.59) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4540728 | 0.80 | HTT (0.60) | HTTALOX15NPC1RAB9ALCK | |
| SCHEMBL17203103 | 0.80 | HTT (0.60) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30718816 | 0.80 | HTT (0.60) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22095066 | 0.78 | HTT (0.52) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6180023 | 0.78 | NPC1 (0.55) | HTTALOX15NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1535334 | 0.78 | HTT (0.59) | HTTALOX15NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-06 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123482-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024876-A1 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | HTT 1786/4885ALOX15 2171/4885NPC1 3742/4885 |
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | HTT 3273/4885ALOX15 386/4885NPC1 879/4885 |
| US-12291504-B2 | Small molecule inhibition of sulfotransferase SULT1A3 | SULT1A1, SULT2A1, SULT1E1 | HTT 1786/4885ALOX15 2171/4885NPC1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.